PROK
ProKidney Corp. (NASDAQ)
Healthcare — Biotechnology
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Price History
Fundamentals
| Market Cap | $570.89M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.28 |
| EPS (TTM) | $-0.53 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -1.70% |
| ROE | -49.37% |
| Debt/Equity | 1.44 |
| Recommendation | None |
| Analyst Target | $6.25 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 63.1 |
| Beta | 1.70 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.13 |
| 52-Week Low | $0.59 |
| 50-Day Avg | $1.81 |
| 200-Day Avg | $2.22 |
| Avg Volume | $1.12M |
| Volume | $1.38M |
Performance Analysis
NEUTRALPROK presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report